Vietnam Patent Expands Global Protection for Recce’s Anti-Infective Platform
Recce Pharmaceuticals Limited (ASX: RCE) has strengthened its global intellectual property portfolio after securing a Family 4 patent in Vietnam for its RECCE® anti-infective technologies, with protection extending until 2041. The patent covers RECCE® 327 (R327) and RECCE® 529 (R529), including manufacturing methods, therapeutic applications against bacterial and viral infections, and multiple delivery options such as oral, inhalation, injectable and topical formulations. The patent coverage extends to therapies being developed for a broad range of infectious diseases, including bacterial skin conditions, diabetic foot complications, burn-related infections, respiratory infections, urinary tract infections, gonorrhoea, influenza, and COVID-19.
The latest approval marks Recce’s eighth Family 4 patent, reinforcing its presence across key international pharmaceutical markets while expanding its reach into Southeast Asia. Vietnam represents a strategically attractive market due to rising pharmaceutical demand and the growing challenge of antimicrobial resistance. The company believes the strengthened patent coverage will support future commercialisation of its synthetic anti-infective platform, which is designed to combat drug-resistant pathogens and address significant unmet medical needs worldwide.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Vietnam Patent Expands Global Protection for Recce’s Anti-Infective Platform
Recce Pharmaceuticals Limited (ASX: RCE) has strengthened its global intellectual property portfolio after securing a Family 4 patent in Vietnam for its RECCE® anti-infective technologies, with protection extending until 2041. The patent covers RECCE® 327 (R327) and RECCE® 529 (R529), including manufacturing methods, therapeutic applications against bacterial and viral infections, and multiple delivery options such as oral, inhalation, injectable and topical formulations. The patent coverage extends to therapies being developed for a broad range of infectious diseases, including bacterial skin conditions, diabetic foot complications, burn-related infections, respiratory infections, urinary tract infections, gonorrhoea, influenza, and COVID-19.
The latest approval marks Recce’s eighth Family 4 patent, reinforcing its presence across key international pharmaceutical markets while expanding its reach into Southeast Asia. Vietnam represents a strategically attractive market due to rising pharmaceutical demand and the growing challenge of antimicrobial resistance. The company believes the strengthened patent coverage will support future commercialisation of its synthetic anti-infective platform, which is designed to combat drug-resistant pathogens and address significant unmet medical needs worldwide.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au